This month PME leads on how companies are being forced to diversify and specialise their business models in our Explosive Evolution cover feature.
With the UK’s June 23 EU membership referendum vote fast approaching we roundup the industry implications of Brexit, which can best be summed up as ‘bad for business’ when it comes to the country’s life science base.
And we speak to Sobi’s UK and Ireland general manager Neil Dugdale about the opportunities to tackle rare diseases in the UK and his company’s successes with orphan drugs.
The issue also asks whether pharma is harnessing the full emotional power of brand creativity.
Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
PME is also available to download as an app for iPhone and iPad
